Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications. Its lead program, ORKA-001, targets IL-23p19 with extended half-life YTE technology for infrequent dosing, and its co-lead program, ORKA-002, targets IL-17A/F for psoriasis, hidradenitis suppurativa, psoriatic arthritis, and other conditions. The company was formed through the merger of ARCA biopharma and Pre-Merger Oruka Therapeutics in August 2024.
Q2 FY2026 — expected 2026-09-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001213900-26-026929 | EDGAR | 88K words |
| 2025-03-06 | 2024-12-31 | 0001213900-25-021165 | EDGAR | — |
| 2024-02-01 | 2023-12-31 | 0000950170-24-009809 | EDGAR | — |
| 2023-02-24 | 2022-12-31 | 0000950170-23-004379 | EDGAR | — |
| 2022-03-14 | 2021-12-31 | 0001564590-22-010075 | EDGAR | — |
| 2021-03-18 | 2020-12-31 | 0001564590-21-014148 | EDGAR | — |
| 2020-02-18 | 2019-12-31 | 0001564590-20-005032 | EDGAR | — |
| 2019-02-27 | 2018-12-31 | 0001564590-19-004882 | EDGAR | — |
| 2018-03-22 | 2017-12-31 | 0001564590-18-006566 | EDGAR | — |
| 2017-03-21 | 2016-12-31 | 0001564590-17-004897 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001213900-25-109182 | EDGAR | 53K words |
| 2025-08-11 | 2025-06-30 | 0001213900-25-074281 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001213900-25-043279 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001213900-24-097443 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0000950170-24-089246 | EDGAR | — |
| 2024-04-25 | 2024-03-31 | 0000950170-24-048329 | EDGAR | — |
| 2023-10-18 | 2023-09-30 | 0000950170-23-053972 | EDGAR | — |
| 2023-07-21 | 2023-06-30 | 0000950170-23-033834 | EDGAR | — |
| 2023-04-24 | 2023-03-31 | 0000950170-23-014091 | EDGAR | — |
| 2022-10-28 | 2022-09-30 | 0001564590-22-035668 | EDGAR | — |
| 2022-08-02 | 2022-06-30 | 0001564590-22-027468 | EDGAR | — |
| 2022-05-02 | 2022-03-31 | 0001564590-22-017043 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2025-12-11 | 0001213900-25-120676 | EDGAR | 1K words |
| 2025-09-22 | 0001213900-25-090129 | EDGAR | — |
| 2025-07-01 | 0001213900-25-060352 | EDGAR | — |
| 2025-06-03 | 0001213900-25-050756 | EDGAR | — |
| 2025-02-05 | 0001213900-25-010525 | EDGAR | — |
| 2024-12-19 | 0001213900-24-110303 | EDGAR | — |
| 2024-11-18 | 0001213900-24-099645 | EDGAR | — |
| 2024-11-14 | 0001213900-24-098530 | EDGAR | — |
| 2024-10-04 | 0001213900-24-085543 | EDGAR | — |
| 2024-09-13 | 0001213900-24-078549 | EDGAR | — |
399 total filings indexed. 367 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000907654 |
| Ticker | ORKA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.orukatx.com |
| Listed | 2024-09-03 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report